TY - JOUR
T1 - Involvement of α-4 integrins in allergic airway responses and mast cell degranulation in vivo
AU - Hojo, Masayuki
AU - Maghni, Karim
AU - Issekutz, Thomas B.
AU - Martin, James G.
PY - 1998
Y1 - 1998
N2 - Antibodies against integrins have been shown to inhibit allergic airway responses. The purpose of this study was to test the hypothesis that the β1 integrin, very late antigen-4 (VLA-4), is involved in mast cell activation triggered by allergen exposure in sensitized animals. To do this we studied Brown Norway rats that were sensitized to ovalbumin (OA; 1 mg subcutaneously) using Borderella pertussis as an adjuvant. Two weeks later rats were challenged with OA, pulmonary resistance (RL) was determined, and the concentrations of histamine and tryptase in bronchoalveolar lavage fluid and N-acetyl-leukotriene (LT)E4 in bile were measured. Pretreatment with a monoclonal antibody against VLA-4 (TA-2) attenuated the early response after OA challenge (342.9 ± 24.4% baseline RL versus 153.3 ± 19.4%; p < 0.01). There were significantly lower concentrations of histamine (67.11 ± 11.90 μg/ml versus 26.69 ± 1.84; p < 0.01) and tryptase (0.143 ± 0.035 μg/ml versus 0.053 ± 0.022 μg/ml; p < 0.01) in TA-2-treated animals. The increases in the concentrations of biliary N-acetyl-LTE4 after OA challenge were also significantly lower in TA-2-treated animals. These data suggest that a selective anti-VLA-4 monoclonal antibody prevents early responses through inhibition of mast cell activation.
AB - Antibodies against integrins have been shown to inhibit allergic airway responses. The purpose of this study was to test the hypothesis that the β1 integrin, very late antigen-4 (VLA-4), is involved in mast cell activation triggered by allergen exposure in sensitized animals. To do this we studied Brown Norway rats that were sensitized to ovalbumin (OA; 1 mg subcutaneously) using Borderella pertussis as an adjuvant. Two weeks later rats were challenged with OA, pulmonary resistance (RL) was determined, and the concentrations of histamine and tryptase in bronchoalveolar lavage fluid and N-acetyl-leukotriene (LT)E4 in bile were measured. Pretreatment with a monoclonal antibody against VLA-4 (TA-2) attenuated the early response after OA challenge (342.9 ± 24.4% baseline RL versus 153.3 ± 19.4%; p < 0.01). There were significantly lower concentrations of histamine (67.11 ± 11.90 μg/ml versus 26.69 ± 1.84; p < 0.01) and tryptase (0.143 ± 0.035 μg/ml versus 0.053 ± 0.022 μg/ml; p < 0.01) in TA-2-treated animals. The increases in the concentrations of biliary N-acetyl-LTE4 after OA challenge were also significantly lower in TA-2-treated animals. These data suggest that a selective anti-VLA-4 monoclonal antibody prevents early responses through inhibition of mast cell activation.
UR - http://www.scopus.com/inward/record.url?scp=0031739745&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031739745&partnerID=8YFLogxK
U2 - 10.1164/ajrccm.158.4.9804001
DO - 10.1164/ajrccm.158.4.9804001
M3 - Article
C2 - 9769271
AN - SCOPUS:0031739745
SN - 1073-449X
VL - 158
SP - 1127
EP - 1133
JO - American Journal of Respiratory and Critical Care Medicine
JF - American Journal of Respiratory and Critical Care Medicine
IS - 4
ER -